Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

First Hookwarm Vaccine Passes Safety Trial

by Global Biodefense Staff
October 8, 2014
Hookworm Strongyloides

Hookworm Strongyloides. Credit; Dr. Mae Melvin/CDC

The first vaccine against hookworm has been shown to be safe in clinical trials in Brazil, according to researchers from the Sabin Vaccine Institute Product Development Partnership who led the trial.

The vaccine—which was developed by the HOOKVAC consortium—was well tolerated by 102 healthy volunteers, and blood tests indicated they developed an immune response.

Hookworms are parasites that infect more than 600 million people globally by attaching themselves to a host’s intestines and feeding off his or her blood. Hookworm infections can leads to conditions such as iron deficiency and capillary damage, as well as impede a child’s mental development and growth.

Researchers hope that a vaccine will serve as an alternative way to handle repeat hookworm infections. Although drugs do exist to kill the hookworms, individuals are often re-infected through contaminated water. An effective vaccine could both treat existing infections and provide lasting immunity against reinfection.

“A vaccine able to induce long-lasting immunity, which could be incorporated into existing vaccination programmes in countries like Brazil, would provide a sustainable solution to the problem of hookworm,” said David Diemert, director of clinical trials at Sabin.

Diemert says it could be several years until the vaccine has undergone the necessary tests to be approved for use, but hopes the vaccine will be available and licensed by 2020.

To read more about the hookworm vaccine trial, click here.

Tags: Vaccines

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC